Abstract
Summary
Carbapenem antibacterial drugs have a broad antibacterial spectrum and strong antibacterial activity. They have antibacterial effects on both aerobic and anaerobic bacteria, especially on multi-drug resistant Gram-negative bacilli, such as extended-spectrum β-lactamase-producing ( ESBL) Enterobacteriaceae bacteria have strong antibacterial activity. This type of drug has a wide range of clinical indications and plays an important role in the antibacterial treatment of multi-drug-resistant bacterial infections, mixed infections of aerobic and anaerobic bacteria, severe infections and infections in patients with immunodeficiency.
The global Carbapenem Antibacterial Drugs market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Carbapenem Antibacterial Drugs Industry Forecast” looks at past sales and reviews total world Carbapenem Antibacterial Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Carbapenem Antibacterial Drugs sales for 2024 through 2030. With Carbapenem Antibacterial Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Carbapenem Antibacterial Drugs industry.
This Insight Report provides a comprehensive analysis of the global Carbapenem Antibacterial Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Carbapenem Antibacterial Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Carbapenem Antibacterial Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Carbapenem Antibacterial Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Carbapenem Antibacterial Drugs.
United States market for Carbapenem Antibacterial Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Carbapenem Antibacterial Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Carbapenem Antibacterial Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Carbapenem Antibacterial Drugs players cover Shandong New Era Pharmaceutical, Shenzhen Haibin Pharmaceutical, Sinopharm Guorui Pharmaceutical, Taiwan Biotech Co., Ltd. and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Carbapenem Antibacterial Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Doripenem
Ertapenem
Imipenem
Meropenem
Panipenem
Biapenem
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Shandong New Era Pharmaceutical
Shenzhen Haibin Pharmaceutical
Sinopharm Guorui Pharmaceutical
Taiwan Biotech Co., Ltd.
Merck
Sun Pharmaceutical Industries Ltd.
JW Pharmaceutical
Zhengde Pharmaceutical
Hospira Inc.
WG Critical Care
Hanhui Pharmaceutical
Zhuhai United Laboratories
ACS Dobfar S.p.A
Iterum Therapeutics plc (ITRM)
Daewoong Pharmaceutical
Aurobindo Pharma Ltd
Sumitomo Pharma
Pfizer Inc.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Carbapenem Antibacterial Drugs market?
What factors are driving Carbapenem Antibacterial Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Carbapenem Antibacterial Drugs market opportunities vary by end market size?
How does Carbapenem Antibacterial Drugs break out type, application?
The global Carbapenem Antibacterial Drugs market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Carbapenem Antibacterial Drugs Industry Forecast” looks at past sales and reviews total world Carbapenem Antibacterial Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Carbapenem Antibacterial Drugs sales for 2024 through 2030. With Carbapenem Antibacterial Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Carbapenem Antibacterial Drugs industry.
This Insight Report provides a comprehensive analysis of the global Carbapenem Antibacterial Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Carbapenem Antibacterial Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Carbapenem Antibacterial Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Carbapenem Antibacterial Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Carbapenem Antibacterial Drugs.
United States market for Carbapenem Antibacterial Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Carbapenem Antibacterial Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Carbapenem Antibacterial Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Carbapenem Antibacterial Drugs players cover Shandong New Era Pharmaceutical, Shenzhen Haibin Pharmaceutical, Sinopharm Guorui Pharmaceutical, Taiwan Biotech Co., Ltd. and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Carbapenem Antibacterial Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Doripenem
Ertapenem
Imipenem
Meropenem
Panipenem
Biapenem
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Shandong New Era Pharmaceutical
Shenzhen Haibin Pharmaceutical
Sinopharm Guorui Pharmaceutical
Taiwan Biotech Co., Ltd.
Merck
Sun Pharmaceutical Industries Ltd.
JW Pharmaceutical
Zhengde Pharmaceutical
Hospira Inc.
WG Critical Care
Hanhui Pharmaceutical
Zhuhai United Laboratories
ACS Dobfar S.p.A
Iterum Therapeutics plc (ITRM)
Daewoong Pharmaceutical
Aurobindo Pharma Ltd
Sumitomo Pharma
Pfizer Inc.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Carbapenem Antibacterial Drugs market?
What factors are driving Carbapenem Antibacterial Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Carbapenem Antibacterial Drugs market opportunities vary by end market size?
How does Carbapenem Antibacterial Drugs break out type, application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Carbapenem Antibacterial Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Carbapenem Antibacterial Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Carbapenem Antibacterial Drugs by Country/Region, 2019, 2023 & 2030
2.2 Carbapenem Antibacterial Drugs Segment by Type
2.2.1 Doripenem
2.2.2 Ertapenem
2.2.3 Imipenem
2.2.4 Meropenem
2.2.5 Panipenem
2.2.6 Biapenem
2.3 Carbapenem Antibacterial Drugs Sales by Type
2.3.1 Global Carbapenem Antibacterial Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Carbapenem Antibacterial Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Carbapenem Antibacterial Drugs Sale Price by Type (2019-2024)
2.4 Carbapenem Antibacterial Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Carbapenem Antibacterial Drugs Sales by Application
2.5.1 Global Carbapenem Antibacterial Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Carbapenem Antibacterial Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Carbapenem Antibacterial Drugs Sale Price by Application (2019-2024)
3 Global Carbapenem Antibacterial Drugs by Company
3.1 Global Carbapenem Antibacterial Drugs Breakdown Data by Company
3.1.1 Global Carbapenem Antibacterial Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Carbapenem Antibacterial Drugs Sales Market Share by Company (2019-2024)
3.2 Global Carbapenem Antibacterial Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Carbapenem Antibacterial Drugs Revenue by Company (2019-2024)
3.2.2 Global Carbapenem Antibacterial Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Carbapenem Antibacterial Drugs Sale Price by Company
3.4 Key Manufacturers Carbapenem Antibacterial Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Carbapenem Antibacterial Drugs Product Location Distribution
3.4.2 Players Carbapenem Antibacterial Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Carbapenem Antibacterial Drugs by Geographic Region
4.1 World Historic Carbapenem Antibacterial Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Carbapenem Antibacterial Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Carbapenem Antibacterial Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Carbapenem Antibacterial Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Carbapenem Antibacterial Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Carbapenem Antibacterial Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Carbapenem Antibacterial Drugs Sales Growth
4.4 APAC Carbapenem Antibacterial Drugs Sales Growth
4.5 Europe Carbapenem Antibacterial Drugs Sales Growth
4.6 Middle East & Africa Carbapenem Antibacterial Drugs Sales Growth
5 Americas
5.1 Americas Carbapenem Antibacterial Drugs Sales by Country
5.1.1 Americas Carbapenem Antibacterial Drugs Sales by Country (2019-2024)
5.1.2 Americas Carbapenem Antibacterial Drugs Revenue by Country (2019-2024)
5.2 Americas Carbapenem Antibacterial Drugs Sales by Type
5.3 Americas Carbapenem Antibacterial Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Carbapenem Antibacterial Drugs Sales by Region
6.1.1 APAC Carbapenem Antibacterial Drugs Sales by Region (2019-2024)
6.1.2 APAC Carbapenem Antibacterial Drugs Revenue by Region (2019-2024)
6.2 APAC Carbapenem Antibacterial Drugs Sales by Type
6.3 APAC Carbapenem Antibacterial Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Carbapenem Antibacterial Drugs by Country
7.1.1 Europe Carbapenem Antibacterial Drugs Sales by Country (2019-2024)
7.1.2 Europe Carbapenem Antibacterial Drugs Revenue by Country (2019-2024)
7.2 Europe Carbapenem Antibacterial Drugs Sales by Type
7.3 Europe Carbapenem Antibacterial Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Carbapenem Antibacterial Drugs by Country
8.1.1 Middle East & Africa Carbapenem Antibacterial Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Carbapenem Antibacterial Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Carbapenem Antibacterial Drugs Sales by Type
8.3 Middle East & Africa Carbapenem Antibacterial Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Carbapenem Antibacterial Drugs
10.3 Manufacturing Process Analysis of Carbapenem Antibacterial Drugs
10.4 Industry Chain Structure of Carbapenem Antibacterial Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Carbapenem Antibacterial Drugs Distributors
11.3 Carbapenem Antibacterial Drugs Customer
12 World Forecast Review for Carbapenem Antibacterial Drugs by Geographic Region
12.1 Global Carbapenem Antibacterial Drugs Market Size Forecast by Region
12.1.1 Global Carbapenem Antibacterial Drugs Forecast by Region (2025-2030)
12.1.2 Global Carbapenem Antibacterial Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Carbapenem Antibacterial Drugs Forecast by Type
12.7 Global Carbapenem Antibacterial Drugs Forecast by Application
13 Key Players Analysis
13.1 Shandong New Era Pharmaceutical
13.1.1 Shandong New Era Pharmaceutical Company Information
13.1.2 Shandong New Era Pharmaceutical Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.1.3 Shandong New Era Pharmaceutical Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Shandong New Era Pharmaceutical Main Business Overview
13.1.5 Shandong New Era Pharmaceutical Latest Developments
13.2 Shenzhen Haibin Pharmaceutical
13.2.1 Shenzhen Haibin Pharmaceutical Company Information
13.2.2 Shenzhen Haibin Pharmaceutical Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.2.3 Shenzhen Haibin Pharmaceutical Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Shenzhen Haibin Pharmaceutical Main Business Overview
13.2.5 Shenzhen Haibin Pharmaceutical Latest Developments
13.3 Sinopharm Guorui Pharmaceutical
13.3.1 Sinopharm Guorui Pharmaceutical Company Information
13.3.2 Sinopharm Guorui Pharmaceutical Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.3.3 Sinopharm Guorui Pharmaceutical Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Sinopharm Guorui Pharmaceutical Main Business Overview
13.3.5 Sinopharm Guorui Pharmaceutical Latest Developments
13.4 Taiwan Biotech Co., Ltd.
13.4.1 Taiwan Biotech Co., Ltd. Company Information
13.4.2 Taiwan Biotech Co., Ltd. Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.4.3 Taiwan Biotech Co., Ltd. Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Taiwan Biotech Co., Ltd. Main Business Overview
13.4.5 Taiwan Biotech Co., Ltd. Latest Developments
13.5 Merck
13.5.1 Merck Company Information
13.5.2 Merck Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.5.3 Merck Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Merck Main Business Overview
13.5.5 Merck Latest Developments
13.6 Sun Pharmaceutical Industries Ltd.
13.6.1 Sun Pharmaceutical Industries Ltd. Company Information
13.6.2 Sun Pharmaceutical Industries Ltd. Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.6.3 Sun Pharmaceutical Industries Ltd. Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Sun Pharmaceutical Industries Ltd. Main Business Overview
13.6.5 Sun Pharmaceutical Industries Ltd. Latest Developments
13.7 JW Pharmaceutical
13.7.1 JW Pharmaceutical Company Information
13.7.2 JW Pharmaceutical Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.7.3 JW Pharmaceutical Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 JW Pharmaceutical Main Business Overview
13.7.5 JW Pharmaceutical Latest Developments
13.8 Zhengde Pharmaceutical
13.8.1 Zhengde Pharmaceutical Company Information
13.8.2 Zhengde Pharmaceutical Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.8.3 Zhengde Pharmaceutical Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Zhengde Pharmaceutical Main Business Overview
13.8.5 Zhengde Pharmaceutical Latest Developments
13.9 Hospira Inc.
13.9.1 Hospira Inc. Company Information
13.9.2 Hospira Inc. Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.9.3 Hospira Inc. Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Hospira Inc. Main Business Overview
13.9.5 Hospira Inc. Latest Developments
13.10 WG Critical Care
13.10.1 WG Critical Care Company Information
13.10.2 WG Critical Care Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.10.3 WG Critical Care Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 WG Critical Care Main Business Overview
13.10.5 WG Critical Care Latest Developments
13.11 Hanhui Pharmaceutical
13.11.1 Hanhui Pharmaceutical Company Information
13.11.2 Hanhui Pharmaceutical Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.11.3 Hanhui Pharmaceutical Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Hanhui Pharmaceutical Main Business Overview
13.11.5 Hanhui Pharmaceutical Latest Developments
13.12 Zhuhai United Laboratories
13.12.1 Zhuhai United Laboratories Company Information
13.12.2 Zhuhai United Laboratories Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.12.3 Zhuhai United Laboratories Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Zhuhai United Laboratories Main Business Overview
13.12.5 Zhuhai United Laboratories Latest Developments
13.13 ACS Dobfar S.p.A
13.13.1 ACS Dobfar S.p.A Company Information
13.13.2 ACS Dobfar S.p.A Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.13.3 ACS Dobfar S.p.A Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 ACS Dobfar S.p.A Main Business Overview
13.13.5 ACS Dobfar S.p.A Latest Developments
13.14 Iterum Therapeutics plc (ITRM)
13.14.1 Iterum Therapeutics plc (ITRM) Company Information
13.14.2 Iterum Therapeutics plc (ITRM) Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.14.3 Iterum Therapeutics plc (ITRM) Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Iterum Therapeutics plc (ITRM) Main Business Overview
13.14.5 Iterum Therapeutics plc (ITRM) Latest Developments
13.15 Daewoong Pharmaceutical
13.15.1 Daewoong Pharmaceutical Company Information
13.15.2 Daewoong Pharmaceutical Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.15.3 Daewoong Pharmaceutical Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Daewoong Pharmaceutical Main Business Overview
13.15.5 Daewoong Pharmaceutical Latest Developments
13.16 Aurobindo Pharma Ltd
13.16.1 Aurobindo Pharma Ltd Company Information
13.16.2 Aurobindo Pharma Ltd Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.16.3 Aurobindo Pharma Ltd Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Aurobindo Pharma Ltd Main Business Overview
13.16.5 Aurobindo Pharma Ltd Latest Developments
13.17 Sumitomo Pharma
13.17.1 Sumitomo Pharma Company Information
13.17.2 Sumitomo Pharma Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.17.3 Sumitomo Pharma Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Sumitomo Pharma Main Business Overview
13.17.5 Sumitomo Pharma Latest Developments
13.18 Pfizer Inc.
13.18.1 Pfizer Inc. Company Information
13.18.2 Pfizer Inc. Carbapenem Antibacterial Drugs Product Portfolios and Specifications
13.18.3 Pfizer Inc. Carbapenem Antibacterial Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Pfizer Inc. Main Business Overview
13.18.5 Pfizer Inc. Latest Developments
14 Research Findings and Conclusion